文献速递肿瘤 PET/CT核素与放射性配体治疗

成纤维细胞激活蛋白抑制剂在肉瘤中的诊疗一体化:当前证据与未来方向

Fibroblast Activation Protein Inhibitor Theranostics in Sarcoma: Current Evidence and Future Directions.
PubMed 文献 · Clin Nucl Med · 2026-02-23

本文综述了成纤维细胞激活蛋白(FAP)抑制剂(FAPI)在肉瘤诊疗一体化中的应用。FAPI-PET/CT在检测原发肿瘤、局部复发和远处转移方面表现出优异的灵敏度和特异度,即使低级别肉瘤亦然。FAPI靶向放射性核素治疗早期临床试验显示有希望的疾病控制率和可管理的毒性,但FAP表达异质性和治疗方案优化仍是挑战。

要点

  • FAPI-PET/CT对肉瘤原发灶、复发和转移检测灵敏度与特异度优异。
  • FAPI靶向放射性核素治疗早期试验显示有希望的疾病控制率和可管理毒性。
  • FAP表达异质性和治疗方案优化是当前主要挑战。

核心结论

  • FAPI诊疗一体化在肉瘤管理中具有改善患者结局的潜力。

研究设计与样本

  • 本文为综述,旨在全面概述FAPI诊疗一体化在肉瘤管理中的当前证据和未来方向。

主要发现

  • FAPI-PET/CT在检测肉瘤原发肿瘤、局部复发和远处转移方面表现出优异的灵敏度和特异度,即使低级别肉瘤亦然。
  • 多种FAPI放射性示踪剂(包括FAPI-04、FAPI-46和FAP-2286)具有独特的药代动力学特性。
  • FAPI靶向放射性核素治疗的早期临床试验显示有希望的疾病控制率和可管理的毒性特征。

关键数值与推荐

  • FAP在多种肉瘤的肿瘤微环境中过表达,已成为有前景的诊疗一体化靶点。
  • FAPI靶向放射性核素治疗使用治疗性放射性同位素向表达FAP的肿瘤细胞递送靶向辐射。

临床怎么用

  • FAPI-PET/CT有助于肉瘤的准确分期和个体化治疗。
  • FAPI靶向放射性核素治疗在早期临床试验中显示有希望的疾病控制率和可管理的毒性,但需优化治疗方案。

局限性

  • FAP表达异质性是需要解决的挑战。
  • 需要优化治疗方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Sarcomas are rare and heterogeneous cancers arising from mesenchymal tissues, presenting diagnostic and therapeutic challenges. Fibroblast activation protein (FAP), overexpressed in the tumor microenvironment of many sarcomas, has emerged as a promising theranostic target. FAP inhibitors (FAPI)-PET/CT demonstrates excellent sensitivity and specificity in detecting primary tumors, local recurrence, and distant metastases, even in low-grade sarcomas. This facilitates accurate staging and personalized treatment. Various FAPI radiotracers, including FAPI-04, FAPI-46, and FAP-2286, offer unique pharmacokinetic properties. FAPI-targeted radionuclide therapy (TRT) employs therapeutic radioisotopes to deliver targeted radiation to FAP-expressing tumor cells. Early clinical trials show promising disease control rates and manageable toxicity profiles. However, challenges remain, including FAP expression heterogeneity and the need for optimized treatment protocols. The aim of this review is to provide a comprehensive overview of the current evidence and future directions of FAPI-based theranostics in sarcoma management, highlighting its potential to improve patient outcomes.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Jafari E, Juweid ME, Jokar N, et al. Fibroblast Activation Protein Inhibitor Theranostics in Sarcoma: Current Evidence and Future Directions. Clin Nucl Med. 2026. PMID: 41738899. doi:10.1097/RLU.0000000000006318

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。